Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 266

1.

Impact of radiation on local regional control in women with node positive breast cancer treated with neoadjuvant chemotherapy and axillary lymph node dissection: Results from ACOSOG 1071 Clinical Trial.

Haffty BG, McCall LM, Ballman KV, Buchholz TA, Hunt KK, Boughey JC.

Int J Radiat Oncol Biol Phys. 2019 May 11. pii: S0360-3016(19)30722-9. doi: 10.1016/j.ijrobp.2019.04.038. [Epub ahead of print]

PMID:
31085287
2.

Surgical Outcomes of Prepectoral Versus Subpectoral Implant-based Breast Reconstruction in Young Women.

Manrique OJ, Banuelos J, Abu-Ghname A, Nguyen MD, Tran NV, Martinez-Jorge J, Harless C, Sharaf B, Jakub JW, Degnim AC, Boughey JC, Jacobson SR.

Plast Reconstr Surg Glob Open. 2019 Mar 13;7(3):e2119. doi: 10.1097/GOX.0000000000002119. eCollection 2019 Mar.

3.

ASO Author Reflections: A Statistical Caution Regarding Missing Clinical Stage in the National Cancer Database.

Hoskin TL, Boughey JC.

Ann Surg Oncol. 2019 Jan 31. doi: 10.1245/s10434-019-07195-0. [Epub ahead of print] No abstract available.

PMID:
30706230
4.

The novel function of tumor protein D54 in regulating pyruvate dehydrogenase and metformin cytotoxicity in breast cancer.

Zhuang Y, Ly RC, Frazier CV, Yu J, Qin S, Fan XY, Goetz MP, Boughey JC, Weinshilboum R, Wang L.

Cancer Metab. 2019 Jan 24;7:1. doi: 10.1186/s40170-018-0193-4. eCollection 2019.

5.

Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.

Boughey JC, Alvarado MD, Lancaster RB, Symmans WF, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Goodellas C, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ; I-SPY2 Investigators.

NPJ Breast Cancer. 2019 Jan 2;5:2. doi: 10.1038/s41523-018-0096-0. eCollection 2019.

6.

PANOPLY: Omics-Guided Drug Prioritization Method Tailored to an Individual Patient.

Kalari KR, Sinnwell JP, Thompson KJ, Tang X, Carlson EE, Yu J, Vedell PT, Ingle JN, Weinshilboum RM, Boughey JC, Wang L, Goetz MP, Suman V.

JCO Clin Cancer Inform. 2018 Dec;2:1-11. doi: 10.1200/CCI.18.00012.

7.

Lessons Learned Regarding Missing Clinical Stage in the National Cancer Database.

Hoskin TL, Boughey JC, Day CN, Habermann EB.

Ann Surg Oncol. 2019 Mar;26(3):739-745. doi: 10.1245/s10434-018-07128-3. Epub 2019 Jan 4.

PMID:
30610561
8.

ASO Author Reflections: Changes in Use of Neoadjuvant Chemotherapy Over Time-Highest Rates of Use Now in Triple-Negative and HER2+ Disease.

Murphy BL, Boughey JC.

Ann Surg Oncol. 2018 Dec;25(Suppl 3):695-696. doi: 10.1245/s10434-018-7046-9. Epub 2018 Nov 21. No abstract available.

PMID:
30465221
9.

Intermediate and long-term outcomes of fibroadenoma excision in adolescent and young adult patients.

Javed A, Jenkins SM, Labow B, Boughey JC, Lemaine V, Neal L, Shah SS, Pruthi S.

Breast J. 2019 Jan;25(1):91-95. doi: 10.1111/tbj.13159. Epub 2018 Nov 16.

PMID:
30444280
10.

ASO Author Reflections: Rate of Axillary Lymph Node Dissection has Decreased in Patients Treated with Neoadjuvant Systemic Therapy.

Nguyen TT, Boughey JC.

Ann Surg Oncol. 2018 Dec;25(Suppl 3):693-694. doi: 10.1245/s10434-018-7045-x. Epub 2018 Nov 12. No abstract available.

PMID:
30421050
11.

A contemporary review of male breast cancer: current evidence and unanswered questions.

Leon-Ferre RA, Giridhar KV, Hieken TJ, Mutter RW, Couch FJ, Jimenez RE, Hawse JR, Boughey JC, Ruddy KJ.

Cancer Metastasis Rev. 2018 Dec;37(4):599-614. doi: 10.1007/s10555-018-9761-x. Review.

PMID:
30232577
12.

Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy.

Barron AU, Hoskin TL, Day CN, Hwang ES, Kuerer HM, Boughey JC.

JAMA Surg. 2018 Sep 5. doi: 10.1001/jamasurg.2018.2696. [Epub ahead of print]

PMID:
30193375
13.

Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial.

Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, Unzeitig GW, Royce ME, Hunt KK.

JAMA Oncol. 2018 Sep 6. doi: 10.1001/jamaoncol.2018.3691. [Epub ahead of print]

PMID:
30193295
14.

Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway.

Kurmi K, Hitosugi S, Yu J, Boakye-Agyeman F, Wiese EK, Larson TR, Dai Q, Machida YJ, Lou Z, Wang L, Boughey JC, Kaufmann SH, Goetz MP, Karnitz LM, Hitosugi T.

Cell Metab. 2018 Dec 4;28(6):833-847.e8. doi: 10.1016/j.cmet.2018.08.008. Epub 2018 Aug 30.

PMID:
30174304
15.

ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer.

Tu X, Kahila MM, Zhou Q, Yu J, Kalari KR, Wang L, Harmsen WS, Yuan J, Boughey JC, Goetz MP, Sarkaria JN, Lou Z, Mutter RW.

Mol Cancer Ther. 2018 Nov;17(11):2462-2472. doi: 10.1158/1535-7163.MCT-18-0470. Epub 2018 Aug 30.

PMID:
30166399
16.

Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.

Boughey JC, Alvarado MD, Lancaster RB, Fraser Symmans W, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ; and I-SPY 2 Investigators.

NPJ Breast Cancer. 2018 Aug 17;4:26. doi: 10.1038/s41523-018-0074-6. eCollection 2018. Review. Erratum in: NPJ Breast Cancer. 2019 Jan 2;5:2.

17.

The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB).

Fayanju OM, Ren Y, Thomas SM, Greenup RA, Plichta JK, Rosenberger LH, Tamirisa N, Force J, Boughey JC, Hyslop T, Hwang ES.

Ann Surg. 2018 Oct;268(4):591-601. doi: 10.1097/SLA.0000000000002953.

18.

HGT-ID: an efficient and sensitive workflow to detect human-viral insertion sites using next-generation sequencing data.

Baheti S, Tang X, O'Brien DR, Chia N, Roberts LR, Nelson H, Boughey JC, Wang L, Goetz MP, Kocher JA, Kalari KR.

BMC Bioinformatics. 2018 Jul 17;19(1):271. doi: 10.1186/s12859-018-2260-9.

19.

The Feasibility of Breast-Conserving Surgery for Multiple Ipsilateral Breast Cancer: An Initial Report from ACOSOG Z11102 (Alliance) Trial.

Rosenkranz KM, Ballman K, McCall L, Kubicky C, Cuttino L, Le-Petross H, Hunt KK, Giuliano A, Van Zee KJ, Haffty B, Boughey JC.

Ann Surg Oncol. 2018 Oct;25(10):2858-2866. doi: 10.1245/s10434-018-6583-6. Epub 2018 Jul 9.

PMID:
29987605
20.

Lymphedema symptoms and limb measurement changes in breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection: results of American College of Surgeons Oncology Group (ACOSOG) Z1071 (Alliance) substudy.

Armer JM, Ballman KV, McCall L, Armer NC, Sun Y, Udmuangpia T, Hunt KK, Mittendorf EA, Byrd DR, Julian TB, Boughey JC.

Support Care Cancer. 2019 Feb;27(2):495-503. doi: 10.1007/s00520-018-4334-7. Epub 2018 Jul 6.

PMID:
29980907
21.

Decreasing Use of Axillary Dissection in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.

Nguyen TT, Hoskin TL, Day CN, Degnim AC, Jakub JW, Hieken TJ, Boughey JC.

Ann Surg Oncol. 2018 Sep;25(9):2596-2602. doi: 10.1245/s10434-018-6637-9. Epub 2018 Jul 5.

PMID:
29978369
22.

Effect of Primary Breast Tumor Location on Axillary Nodal Positivity.

Desai AA, Hoskin TL, Day CN, Habermann EB, Boughey JC.

Ann Surg Oncol. 2018 Oct;25(10):3011-3018. doi: 10.1245/s10434-018-6590-7. Epub 2018 Jul 2.

PMID:
29968027
23.

'Nudging' Surgeons and Patients to De-Escalation of Surgery for Breast Cancer.

Yao K, Boughey JC.

Ann Surg Oncol. 2018 Oct;25(10):2777-2780. doi: 10.1245/s10434-018-6588-1. Epub 2018 Jul 2. No abstract available.

PMID:
29968025
24.

Predicting Non-sentinel Lymph Node Metastases in Patients with a Positive Sentinel Lymph Node After Neoadjuvant Chemotherapy.

Barron AU, Hoskin TL, Boughey JC.

Ann Surg Oncol. 2018 Oct;25(10):2867-2874. doi: 10.1245/s10434-018-6578-3. Epub 2018 Jun 28.

PMID:
29956095
25.

Treatment Outcomes for Pleomorphic Lobular Carcinoma In Situ of the Breast.

Desai AA, Jimenez RE, Hoskin TL, Day CN, Boughey JC, Hieken TJ.

Ann Surg Oncol. 2018 Oct;25(10):3064-3068. doi: 10.1245/s10434-018-6591-6. Epub 2018 Jun 26.

PMID:
29947004
26.

Prepectoral Implant-Based Breast Reconstruction with Postmastectomy Radiation Therapy.

Elswick SM, Harless CA, Bishop SN, Schleck CD, Mandrekar J, Reusche RD, Mutter RW, Boughey JC, Jacobson SR, Lemaine V.

Plast Reconstr Surg. 2018 Jul;142(1):1-12. doi: 10.1097/PRS.0000000000004453.

PMID:
29878988
27.

Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+ Subtypes.

Murphy BL, Day CN, Hoskin TL, Habermann EB, Boughey JC.

Ann Surg Oncol. 2018 Aug;25(8):2241-2248. doi: 10.1245/s10434-018-6531-5. Epub 2018 May 21.

PMID:
29786125
28.

Ability of Intraoperative Pathologic Analysis of Ductal Carcinoma In Situ to Guide Selective Use of Sentinel Lymph Node Surgery.

Murphy BL, Gonzalez AB, Keeney MG, Chen B, Conners AL, Henrichsen TL, Degnim AC, Harmsen WS, Boughey JC, Hieken TJ, Habermann EB, Jakub JW.

Am Surg. 2018 Apr 1;84(4):537-542.

PMID:
29712602
29.

DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine.

Yu J, Qin B, Moyer AM, Nowsheen S, Liu T, Qin S, Zhuang Y, Liu D, Lu SW, Kalari KR, Visscher DW, Copland JA, McLaughlin SA, Moreno-Aspitia A, Northfelt DW, Gray RJ, Lou Z, Suman VJ, Weinshilboum R, Boughey JC, Goetz MP, Wang L.

J Clin Invest. 2018 Jun 1;128(6):2376-2388. doi: 10.1172/JCI97924. Epub 2018 Apr 30.

30.

Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer.

West DC, Kocherginsky M, Tonsing-Carter EY, Dolcen DN, Hosfield DJ, Lastra RR, Sinnwell JP, Thompson KJ, Bowie KR, Harkless RV, Skor MN, Pierce CF, Styke SC, Kim CR, de Wet L, Greene GL, Boughey JC, Goetz MP, Kalari KR, Wang L, Fleming GF, Györffy B, Conzen SD.

Clin Cancer Res. 2018 Jul 15;24(14):3433-3446. doi: 10.1158/1078-0432.CCR-17-2793. Epub 2018 Apr 10.

PMID:
29636357
31.

Factors Associated With Positive Margins in Women Undergoing Breast Conservation Surgery.

Murphy BL, Boughey JC, Keeney MG, Glasgow AE, Racz JM, Keeney GL, Habermann EB.

Mayo Clin Proc. 2018 Apr;93(4):429-435. doi: 10.1016/j.mayocp.2017.11.023. Epub 2018 Feb 10.

PMID:
29439832
32.

Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance).

Le-Petross HT, McCall LM, Hunt KK, Mittendorf EA, Ahrendt GM, Wilke LG, Ballman KV, Boughey JC.

AJR Am J Roentgenol. 2018 Mar;210(3):669-676. doi: 10.2214/AJR.17.18295. Epub 2018 Jan 30.

33.

Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study.

Yu J, Qin B, Moyer AM, Sinnwell JP, Thompson KJ, Copland JA 3rd, Marlow LA, Miller JL, Yin P, Gao B, Minter-Dykhouse K, Tang X, McLaughlin SA, Moreno-Aspitia A, Schweitzer A, Lu Y, Hubbard J, Northfelt DW, Gray RJ, Hunt K, Conners AL, Suman VJ, Kalari KR, Ingle JN, Lou Z, Visscher DW, Weinshilboum R, Boughey JC, Goetz MP, Wang L.

Breast Cancer Res. 2017 Dec 6;19(1):130. doi: 10.1186/s13058-017-0920-8.

34.

A comprehensive analysis of breast cancer microbiota and host gene expression.

Thompson KJ, Ingle JN, Tang X, Chia N, Jeraldo PR, Walther-Antonio MR, Kandimalla KK, Johnson S, Yao JZ, Harrington SC, Suman VJ, Wang L, Weinshilboum RL, Boughey JC, Kocher JP, Nelson H, Goetz MP, Kalari KR.

PLoS One. 2017 Nov 30;12(11):e0188873. doi: 10.1371/journal.pone.0188873. eCollection 2017.

35.

Impact of Neoadjuvant Chemotherapy on Nodal Disease and Nodal Surgery by Tumor Subtype.

Al-Hilli Z, Hoskin TL, Day CN, Habermann EB, Boughey JC.

Ann Surg Oncol. 2018 Feb;25(2):482-493. doi: 10.1245/s10434-017-6263-y. Epub 2017 Nov 27.

PMID:
29181679
36.

Influence of Biologic Subtype of Inflammatory Breast Cancer on Response to Neoadjuvant Therapy and Cancer Outcomes.

Hieken TJ, Murphy BL, Boughey JC, Degnim AC, Glazebrook KN, Hoskin TL.

Clin Breast Cancer. 2018 Aug;18(4):e501-e506. doi: 10.1016/j.clbc.2017.10.003. Epub 2017 Oct 7.

PMID:
29089281
37.
38.

Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2- node positive breast cancer-A National Cancer Database study.

Peethambaram PP, Hoskin TL, Day CN, Goetz MP, Habermann EB, Boughey JC.

NPJ Breast Cancer. 2017 Oct 19;3:41. doi: 10.1038/s41523-017-0044-4. eCollection 2017.

39.

Two studies pave the way for preoperative therapy in pancreatic cancer patients.

Katz MH, Ahmad SA, Boughey JC.

Bull Am Coll Surg. 2016 Aug;101(8):57-60.

PMID:
28941435
40.

Why is surgeon qualification important for clinical trials, and how can it be achieved?

Kurtzman SH, Boughey JC, You YN.

Bull Am Coll Surg. 2016 Sep;101(9):51-2. No abstract available.

PMID:
28941372
41.

Improving rectal cancer outcomes through advocacy, education, and research: The OSTRiCh Consortium and the new NAPRC.

Monson JRT, Dietz DW, Boughey JC, You YN.

Bull Am Coll Surg. 2016 Nov;101(11):45-6. No abstract available.

PMID:
28937195
42.

Surgery versus monitoring and endocrine therapy for low-risk DCIS: The COMET Trial.

Youngwirth LM, Boughey JC, Hwang ES.

Bull Am Coll Surg. 2017 Jan;102(1):62-3. No abstract available.

PMID:
28925613
43.

A new approach for advanced gastric cancer: Using PET scans as a biomarker of preoperative chemotherapy efficacy.

Shah M, Strong VE, Boughey JC.

Bull Am Coll Surg. 2017 Feb;102(2):46-8. No abstract available.

PMID:
28925240
44.

In search of the philosopher’s stone: The ALCHEMIST study for lung cancer.

Veeramachaneni N, Wigle D, Boughey JC.

Bull Am Coll Surg. 2017 Mar;102(3):37-8. No abstract available.

PMID:
28920661
45.

Junior investigators: Get engaged in the Alliance for Clinical Trials in Oncology.

Uy GL, Katz MHG, Boughey JC.

Bull Am Coll Surg. 2017 Apr;102(4):62-3.

46.

Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008.

Connolly RM, Fackler MJ, Zhang Z, Zhou XC, Goetz MP, Boughey JC, Walsh B, Carpenter JT, Storniolo AM, Watkins SP, Gabrielson EW, Stearns V, Sukumar S.

Breast Cancer Res Treat. 2018 Jan;167(1):107-116. doi: 10.1007/s10549-017-4503-2. Epub 2017 Sep 16.

47.

Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.

Leon-Ferre RA, Polley MY, Liu H, Gilbert JA, Cafourek V, Hillman DW, Elkhanany A, Akinhanmi M, Lilyquist J, Thomas A, Negron V, Boughey JC, Liu MC, Ingle JN, Kalari KR, Couch FJ, Visscher DW, Goetz MP.

Breast Cancer Res Treat. 2018 Jan;167(1):89-99. doi: 10.1007/s10549-017-4499-7. Epub 2017 Sep 14.

48.

Interventions to promote better conversations about initial treatment for prostate cancer.

Kim SP, Tilburt JC, Boughey JC.

Bull Am Coll Surg. 2017 May;102(5):48-9. No abstract available.

PMID:
28892327
49.

ACS CRP Dissemination and Implementation Committee issues call for participants in pilot project.

Dickson-Witmer D, Blair S, Boughey JC.

Bull Am Coll Surg. 2017 Jun;102(6):48-50.

PMID:
28885810
50.

Gastrectomy for cancer: What are the benefits of a minimally invasive approach?

Strand MS, Strong VE, Fields RC, Boughey JC.

Bull Am Coll Surg. 2017 Jul;102(7):68-70. No abstract available.

PMID:
28885793

Supplemental Content

Loading ...
Support Center